Abivax Shares Jump 38% After Phase 3 Data Eases Cancer-Safety Fears

robot
Abstract generation in progress
Abivax shares surged over 38% on June 30, 2026, after new Phase 3 data eased cancer-safety fears. The rally followed a 43% drop on June 2 after earlier trial data showed a rise in malignancies among patients taking obefazimod.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned